NCT04682548View on ClinicalTrials.gov

Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients

CompletedOBSERVATIONAL
Enrollment

920

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

September 15, 2022

Study Completion Date

September 15, 2022

Conditions
Multiple SclerosisCovid19
Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT04682548 - Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients | Biotech Hunter | Biotech Hunter